Evidence map›Paper›PMID 41278431›Full record

ArticleWorld journal of diabetes2025

Potentially novel surrogate biomarker for diagnosing insulin resistance in type 2 diabetes.

Helen Jiang, David Henley, Fang-Xu Jiang

Abstract readLetter
In one paragraph

Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Helen JiangDepartment of Medicine, Northern Health, Melbourne 3076, Victoria, Australia.
David HenleyDepartment of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Perth 6009, Australia.
Fang-Xu JiangSchool of Biomedical Sciences, The University of Western Australia, Perth 6009, Australia. fang-xu.jiang@perkins.uwa.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) and obesity are growing global pandemics that shares the common characteristic of insulin resistance (IR). IR leads to progressive β-cell failure, worsening T2DM and its cardiovascular complications. Thus, early diagnosis of IR is important to prevent and reverse β-cell dedifferentiation. However, there is a lack of accessible, non-invasive and affordable tools to early diagnose and stratify IR. The gold standard method used in the research setting is the hyperinsulinemic-euglycemic clamp, however it is invasive, laborious, expensive and difficult to apply at a large scale. Hou

Indexed as

Beta-cell dedifferentiationEctopic lipidInsulin resistanceIntramyocellular lipidMagnetic resonance imaging derived biomarkersMetabolic syndromeMultiparametric imagingObesityPersonalised precision medicineType 2 diabetes mellitus

Identifiers

PMID41278431
PMCPMC12635711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.